The results of a phase 3 clinical trial published in JAMA demonstrate that oral lefamulin, a novel antibiotic recently approved by the US Food and Drug Administration (FDA), is non-inferior to oral moxifloxacin for the treatment of community-acquired bacterial pneumonia (CABP).

Lefamulin is a first-in-class, semi-synthetic pleuromutilin antibiotic designed to inhibit the synthesis of bacterial protein, which is required for bacterial growth. It’s indicated for treatment of CABP caused by the most common gram-positive and gram-negative bacteria associated with the disease, including Streptococcus pneumoniae, methicillin-susceptible Staphylococcus aureusMycoplasma pneumoniae, and Haemophilus influenzae.

Credit: iStock, Neustockimages

Read more at CIDRAP…